Co announces that representatives from the company and Schering-Plough (SGP) are finalizing the ASCENT-2 protocol with the FDA. The study is comparing the benefits of weekly Asentar plus Taxotere to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback